269
During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
 ( adverse event: developed ,  four out of the seven patients: Subject, four out of the seven: Subject.Population, moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia: Effect, During clarithromycin coadministration: Treatment, carbamazepine: Treatment, During: Treatment.Time_elapsed, clarithromycin: Treatment.Drug, carbamazepine: Treatment.Drug, clarithromycin: Combination.Drug, carbamazepine: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: developed ,  four out of the seven patients: Subject, four out of the seven: Subject.Population, moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia: Effect, During clarithromycin coadministration: Treatment, carbamazepine: Treatment, During: Treatment.Time_elapsed, clarithromycin: Treatment.Drug, carbamazepine: Treatment.Drug, clarithromycin: Combination.Drug, carbamazepine: Combination.Drug) 